The subcutaneous injections available in the United States are dulaglutide (Trulicity, Eli Lilly, for type 2 diabetes), liraglutide (Victoza, Novo Nordisk, for type 2 diabetes), semaglutide (Ozempic, Novo Nordisk, for type 2 diabetes and Wegovy, for weight loss), tirzepatide (Mounjaro, Eli Lilly, for type 2 diabetes), and Zepbound (Eli Lilly, for weight loss)
Risks and Considerations, While compounded medications can offer some benefits, they also come with significant risks: Lack of Regulation and Testing : Unlike brand-name medications, compounded drugs are not subject to the same testing and FDA approval process
Multiple clinical studies have confirmed semaglutides effectiveness, showing an average reduction of approximately 10% or greater in total body weight for individuals receiving treatment over several months to a year
An unopened Ozempic pen stored in the refrigerator is typically good for up to two years from the date of manufacture
Doctors should look at genetic tests and each patients situation to find the right dose